{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:49Z","timestamp":1790880709646,"version":"4.1.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s40261-022-01196-w","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T01:02:33Z","timestamp":1664586153000},"page":"875-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AVT02: An Adalimumab Biosimilar"],"prefix":"10.1007","volume":"42","author":[{"given":"Connie","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"key":"1196_CR1","unstructured":"European Medicines Agency. Hukyndra (adalimumab): EU assessment report. 2021. https:\/\/www.ema.europa.eu. Accessed 26 Aug 2022."},{"key":"1196_CR2","unstructured":"STADA Arzneimittel AG. Hukyndra (adalimumab): EU prescribing information. 2022. https:\/\/www.ema.europa.eu. Accessed 26 Aug 2022."},{"key":"1196_CR3","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2022.2035359","author":"C Wynne","year":"2022","unstructured":"Wynne C, Schwabe C, Lemech C, et al. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg\/mL) adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert Opin Investig Drugs. 2022. https:\/\/doi.org\/10.1080\/13543784.2022.2035359.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"1196_CR4","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40259-021-00502-w","volume":"35","author":"SR Feldman","year":"2021","unstructured":"Feldman SR, Reznichenko N, Pulka G, et al. Efficacy, safety and immunogenicity of AVT02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase III study. BioDrugs. 2021;35(6):735\u201348.","journal-title":"BioDrugs"},{"key":"1196_CR5","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1136\/annrheumdis-2022-eular.4763","volume":"81","author":"C Wynne","year":"2022","unstructured":"Wynne C, Stroissnig H, Dias R, et al. Multi-center, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adult volunteers [abstract no. AB1586-PARE]. Ann Rheum Dis. 2022;81:1891\u20132.","journal-title":"Ann Rheum Dis"}],"updated-by":[{"DOI":"10.1007\/s40261-022-01211-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000}}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01196-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01196-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T06:29:59Z","timestamp":1666160999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01196-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":5,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01196-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40261-022-01211-0","asserted-by":"object"}]},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"25 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40261-022-01211-0","URL":"https:\/\/doi.org\/10.1007\/s40261-022-01211-0","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Connie Kang is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content. During the peer review process, the manufacturer of AVT02 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}}]}}